--- title: 'Funding Daily Summary: What Happened on October 12, 2026' headline: Desentum raises €28 million for three allergy programs description: The Finnish company’s lead candidate is in Phase 2, with results expected before the end of 2026. url: https://thebench.bio/news/funding/2026-10-12 topic: funding date: '2026-10-12' covers: - '2026-10-12' date_published: '2026-10-12T12:01:24Z' date_modified: '2026-10-12T12:01:24Z' tags: - Industry sources: 1 publisher: TheBench.Bio --- # Funding Daily Summary: What Happened on October 12, 2026 **Desentum raises €28 million for three allergy programs** The Finnish company’s lead candidate is in Phase 2, with results expected before the end of 2026. ## Today in brief Desentum raised €28 million in an oversubscribed equity round to support three allergy immunotherapy programs. [1] The ongoing Phase 2 trial of its lead candidate, DM-101PX, is testing efficacy in about 100 patients, with results expected before year-end. [1] ## Desentum raises €28 million to advance allergy programs The equity financing will fund work on three allergy immunotherapy programs. Springvest arranged the round. [1] Springvest has arranged €54 million for Desentum in total and is also a major shareholder. [1] In a randomized, placebo-controlled Phase 1 study of 30 adults, 24 received DM-101PX. The candidate produced a strong antibody response after 10 weekly injections. [1] Treatment-related adverse events occurred in 22 treated participants. All were mild or moderate, mostly injection-site reactions. [1] Five participants had systemic allergic reactions, and no serious adverse events were reported. [1] The ongoing Phase 2 BASIT study is assessing efficacy in about 100 patients. Results are expected before the end of 2026. [1] ## The day in numbers - **€28 million**: Desentum’s equity financing for three allergy immunotherapy programs [1] - **24 of 30**: Adults who received DM-101PX in the Phase 1 study [1] - **About 100**: Patients in the ongoing Phase 2 BASIT study [1] ## Sources 1. [Desentum secures €28M for faster allergy immunotherapy](), European Biotechnology, 2026-10-12 --- TheBench.Bio wrote this from the reporting cited above, with a language model drafting and editing. [1]: